Scynexis Inc (SCYX) — SEC Filings
Scynexis Inc (SCYX) — 26 SEC filings. Latest: EFFECT (May 11, 2026). Includes 9 8-K, 6 10-Q, 6 SC 13G/A.
View Scynexis Inc on SEC EDGAR
Overview
Scynexis Inc (SCYX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 31, 2026: SCYNEXIS Inc. filed an 8-K on March 31, 2026, reporting on several key events. These include the entry into a material definitive agreement, unregistered sales of equity securities, and other events under Regulation FD disclosure. The filing also includes financial statements and exhibits.
Sentiment Summary
Across 26 filings, the sentiment breakdown is: 3 bearish, 23 neutral. The dominant filing sentiment for Scynexis Inc is neutral.
Filing Type Overview
Scynexis Inc (SCYX) has filed 1 EFFECT, 9 8-K, 6 10-Q, 1 DEF 14A, 2 10-K, 6 SC 13G/A, 1 DEFA14A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (26)
Risk Profile
Risk Assessment: Of SCYX's 16 recent filings, 3 were flagged as high-risk, 6 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $334,000 |
| Net Income | -$8.59 million |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $37.9 million |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Brian Feldman
Industry Context
SCYNEXIS operates in the biotechnology sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely on external funding and strategic partnerships to advance their pipelines. The competitive landscape is intense, with many companies vying for breakthroughs in treating infectious diseases.
Top Tags
10-Q (4) · material-agreement (3) · corporate-governance (3) · regulatory-filing (3) · financials (3) · Biotechnology (2) · Antifungal Drugs (2) · Net Loss (2) · Liquidity Risk (2) · shareholder-vote (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $8.59M | Increased from $2.81M in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $20.87M | Increased from $16.86M in 2024 |
| License agreement revenue for Q3 2025 | $334K | Decreased from $660K in Q3 2024 |
| License agreement revenue for nine months ended Sept 30, 2025 | $1.96M | Decreased from $2.77M in 2024 |
| Research and development expenses for Q3 2025 | $5.45M | Decreased from $8.07M in Q3 2024 |
| Research and development expenses for nine months ended Sept 30, 2025 | $17.74M | Decreased from $22.09M in 2024 |
| Selling, general and administrative expenses for Q3 2025 | $3.29M | Increased from $2.91M in Q3 2024 |
| Cash and cash equivalents and investments as of Sept 30, 2025 | $37.9M | Down from $59.2M at Dec 31, 2024 |
| Accumulated deficit as of Sept 30, 2025 | $397.4M | Indicates significant historical losses |
| Convertible debt paid | $14.0M | Paid during the nine months ended Sept 30, 2025 |
| Net Loss (Q2 2025) | $6.885M | Reduced from $14.458M in Q2 2024 |
| Net Loss (Six Months 2025) | $12.276M | Reduced from $14.047M in Six Months 2024 |
| Accumulated Deficit | $388.8M | As of June 30, 2025, indicating significant historical losses |
| Cash & Investments | $46.5M | As of June 30, 2025, representing capital resources |
| GSK Milestone Billed | $10.0M | Billed in Q2 2025 despite GSK's purported termination |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Scynexis Inc (SCYX)?
Scynexis Inc has 26 recent SEC filings from Jan 2024 to May 2026, including 9 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SCYX filings?
Across 26 filings, the sentiment breakdown is: 3 bearish, 23 neutral. The dominant sentiment is neutral.
Where can I find Scynexis Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Scynexis Inc (SCYX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Scynexis Inc?
Key financial highlights from Scynexis Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SCYX?
The investment thesis for SCYX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Scynexis Inc?
Key executives identified across Scynexis Inc's filings include Brian Feldman.
What are the main risk factors for Scynexis Inc stock?
Of SCYX's 16 assessed filings, 3 were flagged high-risk, 6 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Scynexis Inc?
Forward guidance and predictions for Scynexis Inc are extracted from SEC filings as they are enriched.